Consolidated Statements of Stockholders' Equity (unaudited) - USD ($) $ in Thousands	Total	Share Repurchase Program	Common Stock	Common Stock Accelerated Share Repurchase Agreement	Common Stock Share Repurchase Program	Additional Paid-In Capital	Additional Paid-In Capital Share Repurchase Program	Accumulated Other Comprehensive Income	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2023			29,560,464
Beginning balance at Dec. 31, 2023	$ 572,514		$ 30			$ 917,107		$ 800	$ (345,423)
Stockholders' Equity [Roll Forward]
Stock options exercised (in shares)			88,276
Stock options exercised	3,616					3,616
Vesting of restricted stock units and performance stock units, net (in shares)			41,185
Shares held for tax withholdings (in shares)			(14,373)
Shares held for tax withholdings	(2,848)					(2,848)
Issuance of common stock (in shares)			543
Issuance of common stock	101					101
Stock-based compensation expense	26,322					26,322
Other comprehensive (loss) income	(676)							(676)
Net income (loss)	(10,005)								(10,005)
Ending balance (in shares) at Mar. 31, 2024			29,676,095
Ending balance at Mar. 31, 2024	589,024		$ 30			944,298		124	(355,428)
Beginning balance (in shares) at Dec. 31, 2023			29,560,464
Beginning balance at Dec. 31, 2023	572,514		$ 30			917,107		800	(345,423)
Stockholders' Equity [Roll Forward]
Net income (loss)	18,285
Ending balance (in shares) at Sep. 30, 2024			29,963,260
Ending balance at Sep. 30, 2024	696,562		$ 30			1,021,970		1,700	(327,138)
Beginning balance (in shares) at Mar. 31, 2024			29,676,095
Beginning balance at Mar. 31, 2024	589,024		$ 30			944,298		124	(355,428)
Stockholders' Equity [Roll Forward]
Stock options exercised (in shares)			88,328
Stock options exercised	5,517					5,517
Vesting of restricted stock units and performance stock units, net (in shares)			21,340
Shares held for tax withholdings (in shares)			(10,985)
Shares held for tax withholdings	(1,862)					(1,862)
Issuance of common stock (in shares)			365
Issuance of common stock	85					85
Issuance of common stock for employee stock purchase plan (in shares)			30,158
Issuance of common stock for employee stock purchase plan	3,431					3,431
Stock-based compensation expense	32,322					32,322
Other comprehensive (loss) income	(239)							(239)
Net income (loss)	9,793								9,793
Ending balance (in shares) at Jun. 30, 2024			29,805,301
Ending balance at Jun. 30, 2024	638,071		$ 30			983,791		(115)	(345,635)
Stockholders' Equity [Roll Forward]
Stock options exercised (in shares)			152,106
Stock options exercised	14,226					14,226
Vesting of restricted stock units and performance stock units, net (in shares)			10,273
Shares held for tax withholdings (in shares)			(4,889)
Shares held for tax withholdings	(4,335)					(4,335)
Issuance of common stock (in shares)			469
Issuance of common stock	65					65
Stock-based compensation expense	28,223					28,223
Other comprehensive (loss) income	1,815							1,815
Net income (loss)	18,497								18,497
Ending balance (in shares) at Sep. 30, 2024			29,963,260
Ending balance at Sep. 30, 2024	$ 696,562		$ 30			1,021,970		1,700	(327,138)
Beginning balance (in shares) at Dec. 31, 2024	29,740,176		29,740,176
Beginning balance at Dec. 31, 2024	$ 689,695		$ 30			981,043		536	(291,914)
Stockholders' Equity [Roll Forward]
Stock options exercised (in shares)			73,491
Stock options exercised	6,441					6,441
Vesting of restricted stock units and performance stock units, net (in shares)			199,778
Vesting of restricted stock units and performance stock units, net	(19,192)					(19,192)
Issuance of common stock (in shares)			390
Issuance of common stock	69					69
Stock-based compensation expense	31,056					31,056
Share repurchase of common stock (in shares)		(442,649)		(103,886)	(442,649)
Share repurchase of common stock		$ (75,009)			$ (1)		$ (75,008)
Other comprehensive (loss) income	(309)							(309)
Net income (loss)	2,992								2,992
Ending balance (in shares) at Mar. 31, 2025			29,467,300
Ending balance at Mar. 31, 2025	$ 635,743		$ 29			924,409		227	(288,922)
Beginning balance (in shares) at Dec. 31, 2024	29,740,176		29,740,176
Beginning balance at Dec. 31, 2024	$ 689,695		$ 30			981,043		536	(291,914)
Stockholders' Equity [Roll Forward]
Stock options exercised (in shares)	149,997
Net income (loss)	$ 9,332
Ending balance (in shares) at Sep. 30, 2025	29,053,367		29,053,367
Ending balance at Sep. 30, 2025	$ 666,460		$ 29			948,374		639	(282,582)
Beginning balance (in shares) at Mar. 31, 2025			29,467,300
Beginning balance at Mar. 31, 2025	635,743		$ 29			924,409		227	(288,922)
Stockholders' Equity [Roll Forward]
Stock options exercised (in shares)			43,691
Stock options exercised	2,174					2,174
Vesting of restricted stock units and performance stock units, net (in shares)			28,487
Vesting of restricted stock units and performance stock units, net	(1,732)					(1,732)
Issuance of common stock (in shares)			490
Issuance of common stock	73					73
Issuance of common stock for employee stock purchase plan (in shares)			29,509
Issuance of common stock for employee stock purchase plan	3,255					3,255
Stock-based compensation expense	41,724					41,724
Other comprehensive (loss) income	169							169
Net income (loss)	(3,592)								(3,592)
Ending balance (in shares) at Jun. 30, 2025			29,569,477
Ending balance at Jun. 30, 2025	677,814		$ 29			969,903		396	(292,514)
Stockholders' Equity [Roll Forward]
Stock options exercised (in shares)			11,685
Stock options exercised	144					144
Vesting of restricted stock units and performance stock units, net (in shares)			23,995
Vesting of restricted stock units and performance stock units, net	(1,224)					(1,224)
Issuance of common stock (in shares)			633
Issuance of common stock	84					84
Stock-based compensation expense	29,467					29,467
Share repurchase of common stock (in shares)		(552,423)			(552,423)
Share repurchase of common stock		$ (50,000)					$ (50,000)
Other comprehensive (loss) income	243							243
Net income (loss)	$ 9,932								9,932
Ending balance (in shares) at Sep. 30, 2025	29,053,367		29,053,367
Ending balance at Sep. 30, 2025	$ 666,460		$ 29			$ 948,374		$ 639	$ (282,582)

Inspire Medical Systems, Inc. 10-Q